Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2015.190 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2016.034 | A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2017.198 | A SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY STUDY OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRONICALLY INFECTED WITH HEPATITIS B VIRUS (3) PATIENTS WITH CHRONIC HEPATITIS B |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2016.369 | Sample Collection for the Evaluation of Elecsys® PIVKA-II, AFP-L3 and AFP |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2016.350 | A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic Hepatitis C Virus GT5 or GT6 Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2017.270 | A RANDOMIZED, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7062931 WITH SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND MULTIPLE DOSES AND MODIFIED REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.668 | An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection | Prof. CHAN Henry Lik Yuen |
| 2015.622 | A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects with Chronic Hepatitis B Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2018.104 | A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.353 | Performance of Fibrometer™ V in patients with chronic hepatitis B (HBV) | Prof. CHAN Henry Lik Yuen |
| 2014.415 | Prospective Sample Collection - Evaluation of novel markers for early detection of Hepatocellular Carcinoma (HCC) - | Prof. CHAN Henry Lik Yuen |
| 2017.530 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.658 | A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region | Prof. CHAN Henry Lik Yuen |
| 2015.189 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2016.190 | A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected with Chronic Hepatitis B Virus |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2014.416 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV | Prof. CHAN Henry Lik Yuen |
| 2018.313 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-506, an HBV Capsid Inhibitor, in Healthy Subjects and HBV-DNA Positive Subjects with Chronic HBV Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2013.605 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination with Entecavir in Patients with Chronic Hepatitis B Virus (HBV) Infection, followed by a two-dose open label cohort and an open label single dose cohort in treatment naïve patients | Prof. CHAN Henry Lik Yuen |
| 2013.410 | A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Treatment-Na_ve Subjects with Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects with Chronic Genotype 2 HCV Infection | Prof. CHAN Henry Lik Yuen |
| 2011.233 | A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon α-2a (Pegasys®) versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB) | Prof. CHAN Henry Lik Yuen |
| 2003.382 | A Randomized, Double-blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | Prof. CHAN Henry Lik Yuen |
| 2010.336 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Prof. CHAN Henry Lik Yuen |
| 2019.151 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2019.233 | CATALYST 207: A PHASE 2, PILOT, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC TREATMENT-NAÏVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS | Prof. CHAN Henry Lik Yuen |
| 2013.694 | Genetic Study of Peginterferon Treatment in Hepatitis B: The GIANT -B Study | Prof. CHAN Henry Lik Yuen |
| 2014.354 | Performance of Fibrometer™ S and V in Chinese patients with non alcoholic fatty liver disease (NAFLD) | Prof. CHAN Henry Lik Yuen |
| 2014.488 | A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients with HBeAg-Positive, Chronic Hepatitis B Virus Infection | Dr. CHAN Henry Lik Yuen |
| 2010.093 | Genetic Variation in IL28B and the response to peginterferon treatment in patients with chronic hepatitis B | Dr Chan Henry Lik-Yuen |
| 2009.250 | A randomized, open-label, controlled, exploratory trial to characterize the results of daily oral administration of telbivudine 600mg and tenofovir disproxil fumarate 300mg in combination or telbivudine 600mg or tenofovir disproxil furmarate 300mg monothe | Professor Chan Henry Lik-Yuen |
| 2008.164 | Effect of Alcohol and Caffeine on the Severity of Liver Fibrosis in Chronic Hepatitis B | Prof Chan Henry Lik-Yuen |
| 2009.105 | A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of Lead-in Telbivudine for 24 Weeks with or without Tenofovir Treatment Intensification in Adult Patients with HBeAg-positive Chronic Hepatitis B | Professor Chan Henry Lik-Yuen |
| 2013.156 | A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in Alisporivir-treated chronic Hepatitis C patients | Prof. Chan Henry Lik-Yuen |
| 2011.525 | Colorectal Cancer Screening in Diabetes Patients: A case-control Study (DM Colon Study) | Dr. Chan Heyson |
| 2016.113 | Incidence of venous thromboembolism in inflammatory bowel disease patients in Asia |
Dr. CHAN Heyson Chi Hey 陳智曦 |
| 2013.406 | Comparison of upper GI involvement of asymptomatic Crohn's disease patients in Europe and Asia | Dr. CHAN Heyson Chi Hey |
| 2015.083 | Patient Knowledge of Inflammatory Bowel Disease in Area of Rising Incidence |
Dr. CHAN Heyson Chi Hey 陳智曦 |
| 2009.447 | A case series observational study on the clinical application of a surgical robot in otorhinolaryngology, head and neck surgery compared to historical controls | Dr Chan Hing Sang |
| 2019.668 | Association between hospital admission episode and use of potentially inappropriate medication in geriatric patient according to Beers Criteria: a Hong Kong local hospital experience | Ms. CHAN Hiu Ching |
| 2021.626 | Prevalence and determinants of neonatal jaundice in Hong Kong: A population-based, retrospective analysis |
Dr. CHAN Hiu Ying 陳曉瑩 |
| 2023.540 | Effectiveness of MSK Occupational Therapy Program in treating patients with shoulder pain |
Mr. CHAN Ho Man 陳昊旻 |
| 2013.007 | Determination of optimal holotranscobalamin diagnostic cutoff for vitamin B12 deficiency in local Chinese population - a clinical laboratory evaluation study | Dr. Chan Ho Ming Michael |
| 2011.427 | Survelliance of emerging drugs of abuse in substance abusers | Dr CHAN Ho Ming Michael |
| 2011.350 | Study of the system performance of cobas 8000 clinical chemistry analyzer in a hospital-based clinical laboratory | Dr CHAN Ho Ming, Michael |
| 2019.532 | Evaluation of the effectiveness of acupuncture at L.I.11 Quchi acupoint on knee pain in Hong Kong distance runners: A randomized controlled trial |
Ms. Chan Ho Yan 陳可昕 |
| 2018.049 | Improving workflow of Emergency Medicine Ward (EMW) admission process in North District Hospital (NDH) by using self-administered health assessment form |
Miss CHAN Ho Yi 陳可宜 |
| 2019.695 | A prospective pilot study on the effectiveness of MEDFRAT in reducing falls in Hong Kong Emergency Department |
Miss CHAN Ho Yi 陳可宜 |
| 2023.236 | DECT special application in MSK : Case Series | Dr. CHAN Hoi Ling |
| 2023.168 | Pictorial Review of Breast Augmentations and Their Complications | Dr. CHAN Hoi Ling |
| 2023.207 | Transcatheter Arterial Embolization of Renal Angiomyolipoma Using Ethanol and Lipiodol | Dr. CHAN Hoi Ling |
| 2023.169 | Breast Intraductal Papilloma Diagnosed by Core Needle Biopsy: Prognosis of Vacuum-assisted Excision, Surgical Excision or Follow-up USG | Dr. CHAN Hoi Ling |
Page 56 of 254.